Mycoplasma Hyopneumoniae Antigens Research Articles

Immune responses induced by a combined vaccination with a recombinant chimera of Mycoplasma hyopneumoniae antigens and capsid virus-like particles of porcine circovirus type 2

BackgroundMycoplasma hyopneumoniae (Mhp) and porcine circovirus type 2 (PCV2) are two important pathogens causing Mycoplasma pneumonia of swine (MPS) and porcine circovirus diseases and porcine circovirus-associated diseases (PCVDs/PCVADs), respectively, and resulted in considerable economic loss to the swine industry worldwide. Currently, vaccination is one of the main measures to control these two diseases; however, there are few combination vaccines that can prevent these two diseases. To determine the effect of combination immunization, we developed capsid-derived (Cap) virus-like particles (VLPs) of PCV2 and a new recombinant chimera composed of the P97R1, P46, and P42 antigens of Mhp. Then we investigated the immune responses induced by the immunization with this combination vaccine in mice and piglets.ResultsThe high level antibodies against three protein antigens (P97R1, P46, and P42 of Mhp) were produced after immunization, up to or higher than 1:400,000; the antibody levels in Pro group continuously increased throughout the 42 days for all the antigens tested. The lymphocyte proliferative response in PCV2 group was stronger than that in PBS, VP, Mhp CV in mice. The antibody levels for Cap remained stable and reached the peak at 35 DAI. The IFN-γ and IL-4 in sera were significantly enhanced in the Pro group than that in the negative control-VP group on Day 14 and 28 post-the first immunization in piglets.ConclusionsAbove all, the combination immunization could induce humoral and cellular immune responses against all four antigens in mice and piglets. Therefore, our approach is a simple and effective vaccination strategy to protect pigs against MPS and PCVD/PCVAD.

Pathogenicity of Mycoplasma hyopneumoniae strain in Naturally Infected Slaughtered Pigs in Nigeria: Immunohistochemical and Ultrastructural Studies

Enzootic pneumonia caused by Mycoplasma hyopneumoniae (MHYO) remains a serious concern to swine industry in many countries including Nigeria. MHYO strains isolated from different countries and geographical locations are known to vary in pathogenicity in pigs. There is paucity of information on the pathogenicity of MHYO strain affecting pigs in Nigeria. This study investigated the pathogenicity of MHYO strain in naturally infected slaughtered pigs in Nigeria using immunohistochemistry and electron microscopy. Two hundred and sixty four lungs were randomly collected from abattoirs at Abeokuta, Ibadan and Lagos, Southwest Nigeria. A sub‐sample of 104 pneumonic lungs was selected, processed for routine histopathological examination and immunohistochemistry, while 3 lung tissues were selected for ultrastructural studies. The most significant microscopic changes were suppurative broncho‐interstitial pneumonia associated with varying degrees of lymphoid hyperplasia of the bronchus‐associated lymphoid tissue (BALT) and thickening of alveolar septa due to cellular infiltration. Immunohistochemically, MHYO antigens were detected in 86/104 (82.7%) lungs. Bronchial and bronchiolar epithelial cells typically exhibited a granular brown reaction on the surface, in the BALT and luminal cellular exudates of MHYO‐infected lung tissues. Transmission electron microscopy revealed numerous Mycoplasmas in the lumina of respiratory tract, in between degenerated cilia, while a few Mycoplasmas were located within the alveoli. It is concluded that the MHYO strain detected in this study is pathogenic to pigs and capable of inducing pneumonic lesions, and therefore implicated in the pathogenesis. This is the first investigative study on pathogenicity of MYHO strain in slaughtered pigs in Nigeria.Support or Funding InformationSupport from the Federal University of Agriculture, AbeokutaThis abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

A novel chimeric protein composed of recombinant Mycoplasma hyopneumoniae antigens as a vaccine candidate evaluated in mice

Enzootic Pneumonia (EP) is caused by the Mycoplasma hyopneumoniae pathogenic bacteria, and it represents a significant respiratory disease that is responsible for major economic losses within the pig industry throughout the world. The bacterins that are currently commercially available have been proven to offer only partial protection against M. hyopneumoniae, and the development of more efficient vaccines is required. Several recombinant antigens have been evaluated via different immunization strategies and have been found to be highly immunogenic. This work describes the construction and immunological characterization of a multi-antigen chimera composed of four M. hyopneumoniae antigens: P97R1, P46, P95, and P42. Immunogenic regions of each antigen were selected and combined to encode a single polypeptide. The gene was cloned and expressed in Escherichia coli, and the chimeric protein was recognized by specific antibodies against each subunit, as well as by convalescent pig sera. The immunogenic properties of the chimera were then evaluated in a mice model through two recombinant vaccines that were formulated as follows: (1) purified chimeric protein plus adjuvant or (2) recombinant Escherichia coli bacterin. The immune response induced in BALB/c mice immunized with each formulation was characterized in terms of total IgG levels, IgG1, and IgG2a isotypes against each antigen present in the chimera. The results of the study indicated that novel chimeric protein is a potential candidate for the future development of a more effective vaccine against EP.

Commercial bacterins did not induce detectable levels of antibodies in mice against Mycoplasma hyopneumoniae antigens strongly recognized by swine immune system

Enzootic Pneumonia (EP) caused by Mycoplasma hyopneumoniae results in major economic losses to the swine industry. Hence, the identification of factors that provide protection against EP could help to develop effective vaccines. One such factor that provides partial protection are bacterins. Therefore, the aim of this study was to verify the induction of antibodies against fifteen M. hyopneumoniae antigens, strongly recognized by the swine immune system during natural infection, in mice vaccinated with six commercial bacterins. Each group of mice was inoculated with one bacterin, and seroconversion was assessed by indirect ELISA using recombinant antigens and M. hyopneumoniae 7448 whole cell extract. Sera from one inoculated group recognized antigen MHP_0067, and sera from four inoculated groups recognized antigens MHP_0513 and MHP_0580. None of the bacterins was able to induce seroconversion against the twelve remaining antigens. This absence of a serological response could be attributed to the lack of antigen expression in M. hyopneumoniae strains used in bacterin production. Additionally the partial protection provided by these vaccines could be due to low expression or misfolding of antigens during vaccine preparation. Therefore, the supplementation of bacterins with these recombinant antigens could be a potential alternative in the development of more effective vaccines.

Evaluation of adjuvant effects of fucoidan for improving vaccine efficacy.

Fucoidan is a sulfated polysaccharide derived from brown seaweed, including Fucus vesiculosus. This compound is known to have immunostimulatory effects on various types of immune cells including macrophages and dendritic cells. A recent study described the application of fucoidan as a vaccine adjuvant. Vaccination is regarded as the most efficient prophylactic method for preventing harmful or epidemic diseases. To increase vaccine efficacy, effective adjuvants are needed. In the present study, we determined whether fucoidan can function as an adjuvant using vaccine antigens. Flow cytometric analysis revealed that fucoidan increases the expression of the activation markers major histocompatibility complex class II, cluster of differentiation (CD)25, and CD69 in spleen cells. In combination with Bordetella bronchiseptica antigen, fucoidan increased the viability and tumor necrosis factor-α production of spleen cells. Furthermore, fucoidan increased the in vivo production of antigen-specific antibodies in mice inoculated with Mycoplasma hyopneumoniae antigen. Overall, this study has provided valuable information about the use of fucoidan as a vaccine adjuvant.

Local and systemic immune responses induced by a recombinant chimeric protein containing Mycoplasma hyopneumoniae antigens fused to the B subunit of Escherichia coli heat-labile enterotoxin LTB

A multi-antigen chimera composed of three antigens of Mycoplasma hyopneumoniae (R1, P42, and NrdF) and the mucosal adjuvant Escherichia coli heat-labile enterotoxin B subunit (LTB) was constructed, and its antigenic and immunogenic properties were evaluated in mice and pigs. In addition, we compared the effect of the fusion and co-administration of these proteins in mice. Antibodies against each subunit recognized the chimeric protein. Intranasal and intramuscular immunization of mice with the chimeric protein significantly increased IgG and IgA levels in the serum and tracheobronchial lavages, respectively, against some of the antigens present in the chimeric. Swine immunized with the chimeric protein developed an immune response against all M. hyopneumoniae antigens present in the fusion with a statistically significant difference (P<0.05). The adjuvant rLTB enhanced the immune response in both fused and co-administered antigens; however, better results were obtained with the chimeric protein. This multi-antigen is a promising vaccine candidate that may help control M. hyopneumoniae infection.

Use of serological and mucosal immune responses to Mycoplasma hyopneumoniae antigens P97R1, P46 and P36 in the diagnosis of infection

Currently available ELISAs used to diagnose Mycoplasma hyopneumoniae infection in pigs have high specificity but low sensitivity. To develop more sensitive assays, the kinetics of specific serum IgG and respiratory mucosal sIgA responses against three M. hyopneumoniae antigens, namely, P97R1 (an adhesin protein), P46 (a membrane protein), and P36 (a cytosolic protein), were characterised over 133 days following experimental infection.Immunoglobulin G against the three proteins remained at high concentrations from 28 to 133 days post-infection (dpi), although IgG against P97R1 was detected earlier and was more reactive than the other two antigens under assessment. Mucosal sIgA appeared earlier than serum IgG but did not persist as long; sIgA concentrations against P97R1 were the highest. Seroconversion was detected 2 weeks earlier with the P97R1-based ELISA than with a commercially available ELISA. On analysis of serum samples from five pig farms that did not use a M. hyopneumoniae vaccine, the P97R1-based IgG ELISA demonstrated a 73.6% coincidence rate with the commercial kit. Moreover, this more specific P97R1-based ELISA detected more positive samples than the commercial kit (52.8% vs. 39.2%).It was concluded that the systemic immune response to M. hyopneumoniae infection in pigs was delayed in onset but persistent whereas the mucosal response developed more rapidly but was less sustained. The P97R1 antigen was identified as a suitable serological marker for diagnosing M. hyopneumoniae infection in pigs, particularly early stage infection.

Immune responses of a chimaeric protein vaccine containing Mycoplasma hyopneumoniae antigens and LTB against experimental M. hyopneumoniae infection in pigs

A recombinant chimaeric protein containing three Mycoplasma hyopneumoniae antigens (C-terminal portion of P97, heat shock protein P42, and NrdF) fused to an adjuvant, the B subunit of heat-labile enterotoxin of Escherichia coli (LTB), was used to immunize pigs against enzootic pneumonia. The systemic and local immune responses, as well as the efficacy of the chimaeric protein in inducing protection against experimental M. hyopneumoniae infection were evaluated. In total, 60 male piglets, purchased from a M. hyopneumoniae-free herd, at 4 weeks of age were randomly allocated to six different experimental groups of 10 animals each: recombinant chimaeric protein by intramuscular (IM) (1) or intranasal (IN) (2) administration, commercial bacterin by IM administration (3), and the adjuvant LTB by IM (4, control group A) or IN (5, control group B) administration. All groups were immunized at 24 and 38 days of age and challenged at 52 days of age. The sixth group that was not challenged was used as the negative control (IN [n=5] or IM [n=5] administration of the LTB adjuvant). Compared with the non-challenged group, administration of the chimaeric protein induced significant (P<0.05) IgG and IgA responses against all individual antigens present in the chimaera, but it could not confer a significant protection against M. hyopneumoniae infection in pigs. This lack of effectiveness points towards the need for further studies to improve the efficacy of this subunit-based vaccine approach.

Association of concurrent porcine circovirus (PCV) 2a and 2b infection with PCV associated disease in vaccinated pigs

Investigations were performed to characterize porcine circovirus (PCV) 2 infection in 10week old pigs from a case of apparent vaccine failure. Thirty serum samples were collected from affected or non-affected pigs and tested for anti-PCV2 antibodies and PCV2 DNA. To address potential PCV2 vaccine compliance issues, samples were tested for antibodies against baculovirus and Mycoplasma hyopneumoniae antigens present in the PCV2 vaccine utilized in this herd. Both PCV2a and PCV2b DNA were detected in 76.6% (90% positive for PCV2a, 86.6% positive for PCV2b), anti-PCV2 IgG in 90%, anti-baculovirus IgG in 50%, and anti-M. hyopneumoniae IgG in 43.3% of the samples. Frequency of baculovirus and M. hyopneumoniae seropositive pigs was significantly lower in affected pigs. The finding that only 50% of the pigs developed a detectable immune response to vaccination suggests poor vaccine compliance or efficacy. Concurrent PCV2a and PCV2b infection was common and may have resulted in enhanced PCV2 replication.

Immunisation of mice with Mycoplasma hyopneumoniae antigens P37, P42, P46 and P95 delivered as recombinant subunit or DNA vaccines

Porcine enzootic pneumonia (PEP), which is caused by the fastidious bacterium Mycoplasma hyopneumoniae, is one of the most economically important diseases in the pig industry worldwide. Commercial bacterins provide only partial protection; therefore, the development of more efficient vaccines against PEP is necessary. In this study, the cellular and humoral immune responses elicited by DNA and recombinant subunit vaccines based on the P37, P42, P46 and P95 antigens of M. hyopneumoniae were evaluated after the intramuscular inoculation of BALB/c mice. The expression of the cytokines INFγ, TNFα and IL1 was evaluated by real-time RT-PCR in splenocytes from vaccinated mice. All antigens delivered as subunit vaccines, especially P42 and P95, and the pcDNA3/P46 DNA vaccine were able to elicit strong immune responses. These vaccines induced cellular immune responses and the production of antibodies able to react with native M. hyopneumoniae proteins. Because both cellular and humoral immune responses were induced, P42 and P95 are promising candidates for a recombinant subunit vaccine and P46 is a promising candidate for a DNA vaccine against PEP.

Influence of experimentally induced endogenous production of cortisol on the immune capacity in swine

Field studies have suggested that ‘stressors’, such as transportation and mixing, might interfere with the immune competence of pigs. Therefore, an experimental model was established to study the influence of elevated concentrations of circulating cortisol on the immune capacity in swine. Three experimental groups, with six pigs in each, were immunized twice, 4 weeks apart, with Mycoplasma hyopneumoniae antigen. Endogenous production of cortisol was induced by intramuscular injection of adrenocorticotropic hormone (ACTH) twice daily. One group received ACTH during the week before and after the second immunization, one group during the week after the second immunization only, while one group served as untreated controls.The treatment with ACTH induced high, but physiological, concentrations of cortisol in plasma. Simultaneously, the number of lymphocytes per milliliter blood decreased while the neutrophil number increased. The elevated concentrations of cortisol also coincided with reduced proliferation and interleukin-2 production by blood lymphocytes stimulated with the mitogens concanavalin A and phytohemagglutinin in vitro, while the responses to pokeweed mitogen were less affected. The suppression of mitogen responses was more pronounced in cultures of whole blood than in cultures of purified peripheral blood mononuclear cells (PBMC).Antibody production, induced by M. hyopneumoniae in cultures of purified PBMC was also inhibited by ACTH treatment. Both the rate of increase and the magnitude of the antibody production induced by the primary immunization were reduced. In contrast, no effects of ACTH treatment were recorded for the response to the second immunization or on the serum levels of antibodies to M. hyopneumoniae.The ability of blood leukocytes to produce interferon-α (IFN-α) at exposure in vitro to fixed pseudorabies virus adsorbed to porcine kidney cells increased in all animals shortly after the second immunization with M. hyopneumoniae. The influence of cortisol on the IFN-α-producing capacity was dependent on whether the test was carried out in whole blood cultures or in cultures with purified PBMC. This finding further emphasizes that the relevance of in vitro assays for measuring in vivo phenomena must be carefully scrutinized.

Serum and mucosal antibody responses against Mycoplasma hyopneumoniae following intraperitoneal vaccination and challenge of pigs with M hyopneumoniae

Pigs were immunised intraperitoneally when six weeks old and again at about 10 weeks old with killed Mycoplasma hyopneumoniae antigen prepared in an oil adjuvant. The pigs were challenged with live M hyopneumoniae (Beaufort strain) at between 11 and 15 weeks old. Antigen specific antibody levels for both IgG and IgA classes in serum and respiratory tract secretion were monitored over time. In serum anti- M hyopneumoniae antibody was detected shortly after the second intraperitoneal vaccination and was largely IgG. In respiratory tract secretion the response was observed after challenge, and was primarily IgA. Anti- M hyopneumoniae antibody-containing cells and their immunoglobulin class specificity were monitored in lung and tracheal lamina propria. In lung the majority of anti- M hyopneumoniae-containing cells were IgG, whereas in the tracheal lamina propria the majority were IgA. These results are discussed in terms of the use of intraperitoneal vaccination for the control of M hyopneumoniae infection.

Antigenic characteristics and stability of microencapsulatedMycoplasma hyopneumoniae vaccine

The in vitro stability (temperature, pH, and trypsin) of Mycoplasma hyopneumoniae antigen (MHA) with and without enteric-coated microencapsulation were examined. Microencapsulation of MHA with cellulose acetate phthalate (CAP) is an effective route to produce enteric-coated vaccine microspheres for oral administration. The effect of temperature on the rate of inactivation of MHA was studied by exposing MHA to various temperatures, such as 25, 37, 50 and 60 degrees C. The MHA microspheres were thermally more stable than that of the unencapsulated MHA. The kinetic parameters were observed to follow an Arrhenius-type temperature dependence. The MHA microspheres were also more stable in acidic regions (pH 1.2-4.0) than that of the free one. The enteric-coated MHA microspheres exhibited an excellent enteric function to prevent acidic degradation. A model similar to the well-known Michaelis-Menten equation was formulated to describe the effect of trypsin on the antigenic degradation of MHA. The equilibrium constant K(A) and the maximum reaction velocity V(m) were obtained from experimental data for both free and microencapsulated MHA. Both K(A) and V(m) values of the microencapsulated MHA were smaller than that of the free one, i.e., the resistance to proteolytic enzyme such as trypsin was enhanced by microencapsulation. The storage stability of enteric-coated MHA microspheres has been satisfactorily prolonged that they could preserve more than 90% of original antigenicity after 30 days, and over 80% of antigenicity of MHA was retained in the microspheres for 95 days when it was stored at 4 degrees C.

An Abattoir Survey of Pneumonia and Pleuritis in Slaughter Weight Swine from 9 Selected Herds

Lungs from 191 slaughter pigs with gross lesions indicative of enzootic pneumonia of pigs (EPP) and 80 grossly normal lungs, all originating from 9 different herds, were subjected to microbiological and pathological examinations. The microbiological studies included both bacterial and mycoplasmal culture and also testing for Mycoplasma hyopneumoniae antigen in tissue by indirect immunofluorescent technique. M. hyopneumoniae, Pasteurella multocida and Mycoplasma hyorhinis were detected in 83%, 43% and 37% of the pneumonic lungs, respectively. Mycoplasma flocculare was the most frequently isolated organism in the non-pneumonic lungs. The greatest amounts of macroscopic pneumonia (25.2%) were recorded in lungs with all the three agents M. hyopneumoniae, P. multocida and M. hyorhinis present. The amounts of pneumonia in lungs with M. hyopneumoniae alone and in concurrence with P. multocida, were 9.3% and 15.6%, respectively. M. hyorhinis was also, in this study, associated with higher frequency of diffuse pleuritis. These findings indicate that M. hyorhinis might be involved in the pathogenesis of pneumonia in slaughter pigs. Ninety-six per cent of the isolates of P. multocida from pneumonic lungs could be characterized as type A. In the herds which had the most severe pneumonia problems, toxin production was detected in 83% of the P. multocida strains while only 28% were toxigenic in herds with subclinical to moderate pneumonia problems.

Immunoblotting analysis of antibody response in swine experimentally inoculated with Mycoplasma hyopneumoniae

Serological cross-reactivity among swine mycoplasmas, and porcine antibody response to Mycoplasma hyopneumoniae antigens during experimental infection were investigated by enzyme-linked immunosorbent assay (ELISA) and the immunoblotting technique. Mycoplasmas solubilized with Tween 20 were used as antigen. Cross-reactivity between M. hyopneumoniae and M. flocculare was indicated by ELISA and it was demonstrated by immunoblotting, which revealed that the predominant cross-reactive antigens were components of M. hyopneumoniae with molecular weights of 74 000 (74 K) and 53 K. Further, it was indicated that 96 K, 70 K, 46 K and 38 K antigenic components of M. hyopneumoniae and 67 K, 56 K and 23 K antigens of M. flocculare were specific for the respective species. Antibodies to 96 K, 76 K, 70 K, 53 K, 46 K and 38 K antigens were detected in serum from pigs experimentally infected with M. hyopneumoniae. Of these antibodies, those against the 46 K antigen reacted early and were most consistently detected during experimental infection. Therefore, the antibodies against the 46 K antigen of M. hyopneumoniae proved to be excellent markers of mycoplasmal pneumonia of swine.